Drugs / Icotrokinra
Icotrokinra
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ICOTYDE | — | 2026-03-17 | fda.gov ↗ |
Trials 17 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05703841 | Feb → Apr 2023 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT05062200 | Oct 2021 → Sep 2022 | — | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 1 | NCT04621630 | Nov 2020 → Sep 2021 | — | Protagonist Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06049017 | Oct 2023 → Sep 2024 | ulcerative colitis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT05357755 | Jun 2022 → Mar 2023 | psoriasis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT05364554 | Jun 2022 → Sep 2023 | psoriasis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT05223868 | Feb → Dec 2022 | psoriasis | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07196722 | Oct 2025 → Sep 2028 expected | Crohn disease | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 39 trials | ||||||
| Phase 3 | NCT07196748 | Oct 2025 → Jan 2028 expected | ulcerative colitis | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06934226 | Apr → Nov 2025 overdue | psoriasis | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06878404 | Feb 2025 → Jul 2026 overdue | psoriatic arthritis | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06807424 | Jan 2025 → Feb 2027 expected | psoriatic arthritis | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06220604 | Mar → Nov 2024 overdue | psoriasis | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06295692 | Feb 2024 → Jan 2025 overdue | generalized pustular psoriasis | Janssen Pharmaceutical K.K. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06143878 | Feb → Sep 2024 overdue | psoriasis | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06095102 | Oct 2023 → Jun 2024 overdue | psoriasis | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06095115 | Oct 2023 → Jul 2024 overdue | psoriasis | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | icotrokinra | “Icotrokinra is the first and only targeted oral peptide that selectively binds the IL-23 receptor with high affinity to precisely inhibit IL-23 signaling.” PMID 41424381 ↗ Dec 20257“Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the treatment of plaque psoriasis.” PMID 41191940 ↗ Nov 2025 “Icotrokinra, a targeted oral peptide that selectively binds interleukin-23 receptors, is a new treatment being investigated for this condition.” PMID 41191932 ↗ Nov 2025 “Icotrokinra (formerly JNJ-77242113 or PN-21235) is a targeted oral peptide that selectively inhibits interleukin-23 receptor signaling.” PMID 40629250 ↗ Jul 2025 |
| Known as | JNJ-77242113 | “Icotrokinra (formerly JNJ-77242113 or PN-21235) is a targeted oral peptide that selectively inhibits interleukin-23 receptor signaling.” PMID 40629250 ↗ Jul 2025 |
| Known as | PN-21235 | “Icotrokinra (formerly JNJ-77242113 or PN-21235) is a targeted oral peptide that selectively inhibits interleukin-23 receptor signaling.” PMID 40629250 ↗ Jul 2025 |
| Known as | PN-235 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04621630 ↗ |
| Action | Inhibit | “selectively inhibits interleukin-23 receptor signaling” PMID 40629250 ↗ Jul 2025 |
| Modality | Peptide | “targeted oral peptide” PMID 40629250 ↗ Jul 2025 |
| Route | Oral | “targeted oral peptide” PMID 40629250 ↗ Jul 2025 |
| Target | IL23R | “interleukin-23 receptor signaling” PMID 40629250 ↗ Jul 2025 |